Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Ottawa

$17,500.00

Investigating switched memory B-cells as a marker for humoral immune system recovery in patients with secondary antibody deficiency due to hematological malignancies

FY 2023-24

Summary
Secondary antibody deficiency (SAD) can occur as a result of hematological malignancies (HM) that decrease humoral immunity and increase susceptibility to infections that could be fatal. SAD management in HM is often overlooked and remains an area of unmet need. Currently, immunoglobulin replacement therapy (IGRT) is the standard treatment for SAD that reduces the risk of infection and improves the quality of life (QOL) for these patients. There are no well-established guidelines for IGRT discontinuation despite their high cost and limited availability. An assessment every 4-6 months is suggested, and the decision is ultimately based on clinical judgement of a safe withdrawal. A recent study showed that IGRT discontinuation was successful in 75% of patients with hematological malignancies, indicating that it is indeed possible to reduce unnecessary use of IGRT. Unfortunately, only 9% of patients discontinued treatment during this study period. Therefore, clinicians need a reliable tool to predict the recovery of humoral immunity and the risk of infections in SAD to determine whether IGRT can be safely discontinued. Switched memory B cells (SMB) have great potential as a biomarker for IGRT discontinuation because SMB cell counts are not affected by IGRT as they have a slower recovery rate compared to total B cells, and lower levels of SMB cells have been associated with an increased risk of recurrent infections. Thus, we propose using SMB cell counts to predict safe and successful discontinuation of IGRT in SAD patients. The proportion of SMB cells will be used to assess the recovery of humoral immune function and change in QOL in SAD patients. Overall, the study findings would help reduce unnecessary use of IGRT and mitigate burdens for both patients and clinicians.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
525529
Name
Yazji Dina
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investigating switched memory B-cells as a marker for humoral immune system recovery in patients with secondary antibody deficiency due to hematological malignancies
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Clinical Guidelines; Health Related Quality Of Life; Hematological Malignancies; Humoral Immunity; Igrt Discontinuation; Immunoglobulin Replacement Therapy; Immunoglobulins; Respiratory Infections; Secondary Antibody Deficiency; Switch Memory B-Cells
Abstract
Secondary antibody deficiency (SAD) can occur as a result of hematological malignancies (HM) that decrease humoral immunity and increase susceptibility to infections that could be fatal. SAD management in HM is often overlooked and remains an area of unmet need. Currently, immunoglobulin replacement therapy (IGRT) is the standard treatment for SAD that reduces the risk of infection and improves the quality of life (QOL) for these patients. There are no well-established guidelines for IGRT discontinuation despite their high cost and limited availability. An assessment every 4-6 months is suggested, and the decision is ultimately based on clinical judgement of a safe withdrawal. A recent study showed that IGRT discontinuation was successful in 75% of patients with hematological malignancies, indicating that it is indeed possible to reduce unnecessary use of IGRT. Unfortunately, only 9% of patients discontinued treatment during this study period. Therefore, clinicians need a reliable tool to predict the recovery of humoral immunity and the risk of infections in SAD to determine whether IGRT can be safely discontinued. Switched memory B cells (SMB) have great potential as a biomarker for IGRT discontinuation because SMB cell counts are not affected by IGRT as they have a slower recovery rate compared to total B cells, and lower levels of SMB cells have been associated with an increased risk of recurrent infections. Thus, we propose using SMB cell counts to predict safe and successful discontinuation of IGRT in SAD patients. The proportion of SMB cells will be used to assess the recovery of humoral immune function and change in QOL in SAD patients. Overall, the study findings would help reduce unnecessary use of IGRT and mitigate burdens for both patients and clinicians.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Yazji, Dina
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~